Feasibility and usefulness of recommended screenings at long-term follow-up clinics for hematopoietic cell transplant survivors.
Allogeneic hematopoietic cell transplantation
Hematological disease
Late effects
Long-term follow-up
Screening and prevention
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
25
02
2021
accepted:
11
11
2021
pubmed:
28
11
2021
medline:
1
2
2022
entrez:
27
11
2021
Statut:
ppublish
Résumé
Advances in allogeneic hematopoietic cell transplantation (allo-HCT) have resulted in a growing number of transplant survivors; however, long-term survivors are at risk of developing late complications, and published guidelines recommend screening of this population. We conducted a single-center prospective study to evaluate the adherence to and usefulness of recommended screenings at a long-term follow-up (LTFU) clinic. We included consecutive patients who received allo-HCT at our center from 2014, as well as post-HCT patients visiting our outpatient clinic. Visits and screenings were planned at 3 months, 6 months, and 1 year after allo-HCT, and annually thereafter. Outcomes were reported by physicians including the incidence of findings at each screening that led to interventions. Among the 216 participants, 95% visited the LTFU clinic, and 94% completed planned screenings. However, the rate of secondary cancer screenings targeting high-risk subjects was lower (38% to 68%). The overall percentage of screening results leading to interventions was 4.5%, with higher percentages (> 10%) for bone density testing, ophthalmological examinations, dental assessment, upper gastrointestinal endoscopy, and colonoscopy, with two patients diagnosed with secondary cancers. Although the overall screening rate was high, it should be possible to improve the detection rate of late complications by decreasing screening failures, especially the screening for secondary cancers limited for high-risk survivors. A nationwide effort to educate HCT survivors and health practitioners using standardized nationwide LTFU tools may be effective, along with the development of institutional, local, and nationwide networks to maintain effective follow-up systems.
Identifiants
pubmed: 34837539
doi: 10.1007/s00520-021-06698-5
pii: 10.1007/s00520-021-06698-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2767-2776Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Gyurkocza B, Rezvani A, Storb RF (2010) Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol 3(3):285–299
doi: 10.1586/ehm.10.21
Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363(22):2091–2101
doi: 10.1056/NEJMoa1004383
Horan JT, Logan BR, Agovi-Johnson MA, Lazarus HM, Bacigalupo AA, Ballen KK et al (2011) Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol 29(7):805–813
doi: 10.1200/JCO.2010.32.5001
Kurosawa S, Yakushijin K, Yamaguchi T, Atsuta Y, Nagamura-Inoue T, Akiyama H, et al. Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry. Bone marrow transplantation. 2012 10.
Tanaka Y, Kurosawa S, Tajima K, Tanaka T, Ito R, Inoue Y et al (2016) Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 51(4):553–559
doi: 10.1038/bmt.2015.330
Majhail NS, Tao L, Bredeson C, Davies S, Dehn J, Gajewski JL et al (2013) Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transplant 19(10):1498–1501
doi: 10.1016/j.bbmt.2013.07.020
Martin PJ, Counts GW Jr, Appelbaum FR, Lee SJ, Sanders JE, Deeg HJ et al (2010) Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 28(6):1011–1016
doi: 10.1200/JCO.2009.25.6693
Sun CL, Francisco L, Kawashima T, Leisenring W, Robison LL, Baker KS et al (2010) Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood. 116(17):3129–39; quiz 377
doi: 10.1182/blood-2009-06-229369
Atsuta Y, Suzuki R, Yamashita T, Fukuda T, Miyamura K, Taniguchi S et al (2014) Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease. Ann Oncol 25(2):435–441
doi: 10.1093/annonc/mdt558
Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O et al (2009) Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113(5):1175–1183
doi: 10.1182/blood-2008-05-158782
Tanaka Y, Kurosawa S, Tajima K, Tanaka T, Ito R, Inoue Y et al (2017) Increased incidence of oral and gastrointestinal secondary cancer after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 52(5):789–791
doi: 10.1038/bmt.2017.4
Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C et al (2012) Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant 47(3):337–341
doi: 10.1038/bmt.2012.5
Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ et al (2006) Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 12(2):138–151
doi: 10.1016/j.bbmt.2005.09.012
Kurosawa S (2017) Long-term follow-up clinics after hematopoietic cell transplantation: its needs and challenges in Japan. [Rinsho ketsueki] The Japanese journal of clinical hematology 58(10):2111–23
pubmed: 28978856
Hashmi SK, Lee SJ, Savani BN, Burns L, Wingard JR, Perales MA et al (2018) ASBMT practice guidelines committee survey on long-term follow-up clinics for hematopoietic cell transplant survivors. Biol Blood Marrow Transplant 24(6):1119–1124
doi: 10.1016/j.bbmt.2018.03.023
Saunders IM, Tan M, Koura D, Young R (2020) Long-term follow-up of hematopoietic stem cell transplant survivors: a focus on screening, monitoring, and therapeutics. Pharmacotherapy 40(8):808–841
doi: 10.1002/phar.2443
Khera N, Chow EJ, Leisenring WM, Syrjala KL, Baker KS, Flowers ME et al (2011) Factors associated with adherence to preventive care practices among hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant 17(7):995–1003
doi: 10.1016/j.bbmt.2010.10.023
Hagiwara S, Mochizuki T, Kondo M, Mori A, Fukuda T (2010) Long-term follow-up of patients undergoing allogeneic hematopoietic stem cell transplantation in Japan. [Rinsho ketsueki] The Japanese journal of clinical hematology 51(3):167–73
pubmed: 20379110
Kurosawa S, Kim S, Fuji S, Yamashita T, Tanosaki R, Fukuda T, et al. Long-term follow-up system after allogeneic hematopoietic stem cell transplantation: a single-center feasibility study. Journal of Hematopoietic Cell Transplantation. 2014;3(2).
Guidelines of Japan Society for Hematopoitic Cell Transplantation. Iyaku-Journal. 2017;4.
Tsukagoshi M, Kurosawa S, Munakata W, Makita S, Fukuhara S, Suzuki T, et al. Cross-sectional patient survey on the need for a long-term follow-up program after autologous hematopoietic cell transplantation. Journal of Hematopoietic Cell Transplantation. 2018;7(4).
Kurosawa S, Mori A, Tsukagoshi M, Onishi Y, Ohwada C, Mori T, et al. Current status and needs of long-term follow-up clinics for hematopoietic cell transplantation survivors: results of a nationwide survey in Japan. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020 18.
Bishop MM, Lee SJ, Beaumont JL, Andrykowski MA, Rizzo JD, Sobocinski KA et al (2010) The preventive health behaviors of long-term survivors of cancer and hematopoietic stem cell transplantation compared with matched controls. Biol Blood Marrow Transplant 16(2):207–214
doi: 10.1016/j.bbmt.2009.09.015
Japanese Society for Transplantation and Cellular Therapy. Nationwide standardized LTFU tools. 2021 [cited; Available from: https://www.jshct.com/modules/facility/index.php?content_id=37 . Accessed 1 Jun 2021.